| UCSF |
|
UCSF |
Graft versus Host Disease (GvHD) |
An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients |
Recruiting |
|
| UCSF |
|
Passage Bio Inc. |
GM1 Gangliosidosis |
A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subjects Aged 4 to 24 Months with Type 1 (Early Onset Infant |
Active, not recruiting |
|
| UC Davis |
|
UC Davis |
Eye - Retinopathy |
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy |
Recruiting |
|
| UCI |
|
jCyte |
Eye - Retinitis Pigmentosa (RP) |
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa |
No longer active |
|
| UC Davis |
|
Atara Bio. |
EBV-PTLD |
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) |
No longer active |
|
| UC Davis |
|
Capricor Therapeutics |
Duchenne Muscular Dystrophy |
Open-Lael Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial (HOPE-2-OLE) |
Recruiting |
|
| UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus |
No longer active |
|
| UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
No longer active |
|
| UCSD |
|
Viacyte |
Diabetes - Type 1 |
Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01 |
No longer active |
|
| UCSD |
|
Discgenics |
Degenerative Disc Disease |
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration |
No longer active |
|
| UCSD |
|
UCSD & CIRM |
Cystinosis |
Stem cell gene therapy for cystinosis |
Recruiting |
|
| UCSD |
|
Tigenix |
Crohn's Disease |
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn’s Disease (CD) |
Active, not recruiting |
|
| UCI |
|
Pluristem Ltd. |
Critical Limb Ischemia (CLI) |
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor |
No longer active |
|
| UCSF & UC Davis |
|
|
COVID-19/ARDS |
Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) |
No longer active |
|
| UC Davis |
|
Capricor Therapeutics |
COVID |
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients with Severe COVID-19 |
No longer active |
|
| UCSD |
|
UCSD/Oncternal |
chronic lymphocytic leukemia |
Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax |
Active, not recruiting |
|
| UC Davis |
|
Nohla Therapeutics |
Cancer – Leukemia |
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML |
No longer active |
|
| UCSF |
|
PACT Pharma |
Cancer – Solid Tumor |
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors |
No longer active |
|
| UC Davis |
|
UC Davis |
Cancer - Tongue Dysphagia |
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia |
Recruiting |
|
| UCLA |
Scott Nowicki, MD, PhD
|
UCLA |
Cancer - Solid Tumors |
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies |
No longer active |
|
| City of Hope |
|
Adaptimmune |
Cancer - Sarcoma |
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma |
Active, not recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Prostate |
PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
Recruiting |
|
| City of Hope |
|
Adaptimmune |
Cancer - Ovarian |
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. |
Recruiting |
|
| City of Hope |
|
Tessa Therapeutics |
Cancer - Nasopharyngeal Carcinoma |
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea |
Recruiting |
|
| City of Hope |
|
Atara Bio. |
Cancer - Nasopharyngeal Carcinoma |
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) |
No longer active |
|
| City of Hope |
|
Adaptimmune |
Cancer - Myeloma |
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma |
Recruiting |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Myeloma |
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE) |
Recruiting |
|
| City of Hope |
|
Janssen Research & Development, LLC. |
Cancer - Myeloma |
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) |
Recruiting |
|
| City of Hope |
|
Novartis Pharmaceuticals |
Cancer - Lymphona |
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) |
Recruiting |
|
| UC Davis |
|
UC Davis |
Cancer - Lymphoma (HIV-Related) |
Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Lymphoma (AIDS-Related) |
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma |
Active, not recruiting |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) |
Recruiting |
|
| City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) |
No longer active |
|
| City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) |
Active, not recruiting |
|
| City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1) |
Recruiting |
|
| City of Hope |
|
Celgene |
Cancer - Lymphoma |
An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) |
Recruiting |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) |
Recruiting |
|
| City of Hope |
Elizabeth Budde, MD
626-218-2405 |
Kite Pharma |
Cancer - Lymphoma |
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Lymphoma |
Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) |
Active, not recruiting |
|
| City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) |
Recruiting |
|
| City of Hope |
|
Precision BioSciences, Inc. |
Cancer - Lymphoma |
Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL |
Recruiting |
|
| City of Hope |
|
Torque Therapeutics, Inc. |
Cancer - Lymphoma |
TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas |
Recruiting |
|
| City of Hope |
|
Adaptimmune |
Cancer - Lung |
A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
|
| City of Hope |
|
Adaptimmune |
Cancer - Lung |
A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Recruiting |
|
| City of Hope |
|
Adaptimmune |
Cancer - Lung |
Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC |
Recruiting |
|
| UCLA |
|
UCLA |
Cancer - Lung |
A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
Active, not recruiting |
|
| City of Hope |
|
Glaxo Smith Kline (GSK) |
Cancer - Lung |
Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab |
No longer active |
|
| City of Hope |
|
City of Hope |
Cancer - Leukemia |
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
Recruiting |
|
| UCSD |
|
UCSD |
Cancer - Leukemia |
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia |
No longer active |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Leukemia |
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) |
No longer active |
|
